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Background—Transcatheter aortic valve-in-valve implantation is an emerging therapeutic alternative for patients with a
failed surgical bioprosthesis and may obviate the need for reoperation. We evaluated the clinical results of this technique
using a large, worldwide registry.
Methods and Results—The Global Valve-in-Valve Registry included 202 patients with degenerated bioprosthetic valves (aged
77.710.4 years; 52.5% men) from 38 cardiac centers. Bioprosthesis mode of failure was stenosis (n85; 42%), regurgitation
(n68; 34%), or combined stenosis and regurgitation (n49; 24%). Implanted devices included CoreValve (n124) and
Edwards SAPIEN (n78). Procedural success was achieved in 93.1% of cases. Adverse procedural outcomes included initial
device malposition in 15.3% of cases and ostial coronary obstruction in 3.5%. After the procedure, valve maximum/mean
gradients were 28.414.1/15.98.6 mm Hg, and 95% of patients had 1 degree of aortic regurgitation. At 30-day
follow-up, all-cause mortality was 8.4%, and 84.1% of patients were at New York Heart Association functional class I/II.
One-year follow-up was obtained in 87 patients, with 85.8% survival of treated patients.
Conclusions—The valve-in-valve procedure is clinically effective in the vast majority of patients with degenerated
bioprosthetic valves. Safety and efficacy concerns include device malposition, ostial coronary obstruction, and high
gradients after the procedure. (Circulation. 2012;126:2335-2344.)
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More than 200 000 surgical aortic valve replacements(SAVR) are performed annually worldwide, with a
substantial shift toward the use of bioprostheses rather than
mechanical valves.1 Bioprostheses have limited durability,
and most are expected to degenerate and eventually fail
within 10 to 20 years.2–4 As a result, it is estimated that in the
subsequent few years, many patients will suffer from failed
surgical bioprosthetic valves. Reoperation, the standard of
care for these patients, is occasionally a high-risk procedure
that carries significant mortality and morbidity risks, espe-
cially because many of these patients are elderly and have
numerous comorbidities.5–7
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Editorial see p 2280
Clinical Perspective on p 2344
Transcatheter aortic valve replacement (TAVR), performed
mainly with the use of the Edwards SAPIEN (Edwards
Lifesciences, Irvine, CA) and the CoreValve (Medtronic,
Minneapolis, MN) devices, was introduced as an alternative
to SAVR for the treatment of severe symptomatic native
aortic valve stenosis in patients at a high surgical risk.8–10 In
recent years, several reports have suggested that the off-label
use of TAVR within failed surgically inserted bioprosthetic
valves (valve-in-valve [VIV]) is technically feasible.11–26
However, all previous reports evaluating the VIV approach
have included a small number of cases and are limited in
providing measures of efficacy and safety. High postproce-
dural gradients and several potentially life-threatening com-
plications, such as ostial coronary obstruction, were only
reported anecdotally, and there was no comparison between
different devices possibly applicable for VIV.27–29
The Global Valve-in-Valve Registry was established to mit-
igate these limitations and further explore the VIV approach.
Study objectives were to evaluate the efficacy and safety of this
procedure in a large group of patients. In particular, the study
sought to examine clinical outcomes, including long-term anal-
ysis; to evaluate the results of VIV procedures performed inside
different types of surgical bioprostheses; to give correlates for
high postprocedural gradients; to supply data on possible rare
complications; and to compare the procedural characteristics and
clinical results of performing VIV with the use of Edwards
SAPIEN and CoreValve devices.
Methods
Registry Design
The Global Valve-in-Valve Registry was initiated in December
2010. The registry is not supported by any external funding and was
designed to collect data from centers across the world that had
TAVR experience with the use of either CoreValve or Edwards
SAPIEN devices. There was retrospective collection of data from
cases performed before registry initiation and prospective data
collection after that time.
A total of 38 centers from Europe, North America, Australia, New
Zealand, and the Middle East contributed all of their VIV experience
to the registry (Appendix I in the online-only Data Supplement).
Continued communication with involved centers (D.D.) regarding
clinical events was initiated. Data were collected with the use of a
dedicated case report form. All inconsistencies were resolved di-
rectly with local investigators and on-site data monitoring. For each
bioprosthesis, we collected the operation year, valve type, label size,
and internal diameter. Baseline bioprosthetic valve area, gradients,
and degree of regurgitation were gathered from the last echocardio-
graphic study before the procedure. Early postimplantation hemody-
namic analysis included data from intraprocedural echocardiographic
analysis or from the first echocardiographic evaluation after the
procedure. Images from these procedures were collected into a
library of VIV procedures. The inclusion of patients included in this
registry was approved in each center by a local ethical committee.
Definitions
Bioprosthetic valve mechanism of failure (eg, stenosis or regurgita-
tion) was evaluated according to the criteria of the American Society
of Echocardiography.30 Patients with at least a moderate degree of
both stenosis and regurgitation were included in the “combined
stenosis and regurgitation” group. Other patients were categorized,
according to the primary mechanism of failure, in either the
“stenosis” group or the regurgitation group.
Successful VIV implantation was defined as a procedure having
all of the following: successful vascular access, delivery, and
deployment of a device; successful retrieval of the delivery system;
intended performance of the device with neither severe stenosis
(mean aortic gradient 40 mm Hg or peak velocity 4 m/s) nor
moderate or severe regurgitation; and the patient being transferred
alive out of the catheterization suite. Major clinical end points were
assessed according to the Valve Academic Research Consortium
(VARC) criteria.31 Follow-up data were collected for patients ac-
cording to the time frame elapsed from the index VIV procedure to
data lock for present analysis.
Statistical Analysis
Statistical analysis was performed with the use of SAS version 9.1
(SAS Institute, Cary, NC). Results are presented as meanSD for
continuous variables with normal distribution, as median and inter-
quartile range (25th, 75th percentiles) for continuous variables
without normal distribution, and as percentages for categorical data.
Student t test was used to compare normally distributed continuous
variables between the CoreValve and Edwards SAPIEN groups, and
the Wilcoxon rank sum test was used for variables not normally
distributed. One-way ANOVA was used to compare the stenosis,
regurgitation, and combined groups for normally distributed contin-
uous variables, and the Kruskal-Wallis test was used for non–
normally distributed data. The 2 and Fisher exact tests were used to
compare categorical variables. The Kaplan–Meier method and com-
parison between the CoreValve and Edwards SAPIEN groups were
performed with the use of the log-rank statistic. High postprocedural
gradients were defined according to the VARC criteria as those
having mean gradients 20 mm Hg.31 Changes in valve gradients
were evaluated with repeated measures analysis. For multivariable
analysis of predictors for high postprocedural gradients, a logistic
regression was used. The initial selection of variables entered into
the univariate model included the following: sex, age, functional
class, baseline echocardiographic parameters (aortic valve area,
aortic regurgitation degree, and left ventricular ejection fraction),
bioprosthetic type (stented versus stentless), internal diameter, the
device used during the VIV procedure (CoreValve versus Edwards
SAPIEN), device size, preimplantation valvuloplasty, and postim-
plantation valvuloplasty. Variables with P0.10 in the univariate
analysis, as well as other critical parameters possibly affecting the
analysis (eg, bioprosthesis size or performance of postimplantation
valvuloplasty), were further examined in a stepwise model. The
results of the multivariate analysis are presented as odds ratio with
95% confidence interval (CI). A 2-sided P value 0.05 was
considered statistically significant.
The authors are solely responsible for the design and conduct of
this study, all analyses, drafting and editing of the manuscript, and its
final contents.
Results
Patient Demographics
Table 1 shows the clinical characteristics of 202 patients in-
cluded in the registry; 124 patients underwent VIV procedure
with the use of the CoreValve device and 78 patients with the
use of the Edwards SAPIEN device. Patients’ mean age was
77.710.4 years (distribution, 25–91), and 52.5% were men.
The CoreValve group had lower left ventricular ejection fraction
and a higher rate of diabetes mellitus than did the Edwards
SAPIEN group (4913% versus 52.810.4%, P0.03; 34.7%
versus 20.5%, P0.03, respectively).
Degenerated Bioprosthetic Valves
The patients included in the trial had between 1 and 4
previous SAVRs (85.6% had 1 previous surgery). The me-
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dian time from the last SAVR to the VIV procedure was 9
years (interquartile range, 6 to 13 years). Implanted biopros-
theses were stented in 76.7% of cases (n155) and stentless
in 23.3% (n47). Edwards SAPIEN was used to treat a
higher proportion of stented bioprosthetic valves than Cor-
eValve (87.2% versus 70.2%; P0.005). There was no
significant difference between the CoreValve and Edwards
SAPIEN groups in the internal diameter size of bioprostheses.
Fifty-two patients had small bioprostheses with internal
diameter 20 mm (28.2% of CoreValve cases versus 21.8%
of Edwards-SAPIEN; P0.32). Appendix II in the online-
only Data Supplement includes data on the degenerative
bioprostheses included in the registry.
The mechanism of failure was stenosis (n85; 42.1%),
regurgitation (n68; 33.7%), and combined stenosis and
regurgitation (n49; 24.3%). The distribution of mechanism
of failure did not differ between the CoreValve and Edwards
SAPIEN groups. The stenosis group had lower aortic valve
orifice area and higher maximum/mean valve gradients than
the regurgitation and combined groups (0.690.3 versus
1.630.53 versus 0.910.2 cm2, respectively; 8324.2/
50.516.2 versus 34.614.1/17.87.8 versus 67.716.8/
38.811.1 mm Hg, respectively).
Characteristics of VIV Procedures
Table 2 shows the procedural characteristics and early results
of VIV procedures in the total cohort and is further separated
into the CoreValve and Edwards SAPIEN groups. In both
groups, the majority of devices were of the smallest available
size: 26-mm CoreValve (79.8%) and 23-mm Edwards
SAPIEN (79.5%). The main access route in the CoreValve
group was femoral (91.1%) versus apical in the Edwards
SAPIEN group (69.2%). General anesthesia, transesophageal
echocardiogram, and preimplantation valvuloplasty use were
all more common in the Edwards SAPIEN group.
Table 1. Baseline Characteristics at the Time of Valve-In-Valve Procedure
All
(n202)
CoreValve
(n124)
Edwards SAPIEN
(n78) P *
Patient characteristics
Age, y 77.710.4 77.411 78.39.4 0.53
Men, n (%) 106 (52.5) 65 (52.4) 41 (52.6) 1.0
Log EuroSCORE 31.116.4 3116.6 31.216.1 0.92
STS score 11.89.9 12.811 10.27.5 0.07
Diabetes mellitus, n (%) 59 (29.2) 43 (34.7) 16 (20.5) 0.03
Peripheral vascular disease, n (%) 41(20.3) 22 (17.7) 19 (24.4) 0.26
Chronic renal failure, n (%)† 94 (46.5) 52 (41.9) 42 (53.8) 0.10
Previous stroke, n (%) 25 (12.4) 16 (12.9) 9 (11.5) 0.77
1 previous SAVR, n (%) 31 (15.3) 19 (15.3) 12 (15.4) 1.0
NYHA functional class, n (%) 0.39
II 12 (5.9) 6 (4.8) 6 (7.7)
III 112 (55.4) 66 (53.2) 46 (59)
IV 78 (38.6) 52 (41.9) 26 (33.3)
Left ventricular ejection fraction, % 50.512.2 4913 52.810.4 0.03
Bioprosthetic valve
Time since last SAVR, y‡ 9 (6, 13) 10 (6, 14) 8 (5, 13) 0.33
Type, n (%) 0.01
Stented 155 (76.7) 87 (70.2) 68 (87.2)
Stentless 47 (23.3) 37 (29.8) 10 (12.8)
Size (internal diameter), n (%) 0.27
20 mm 52 (25.7) 35 (28.2) 17 (21.8)
20 and 23 mm 102 (50.5) 57 (46) 45 (57.7)
23 mm 40 (19.8) 27 (21.8) 13 (16.7)
Unknown 8 (4) 5 (4) 3 (3.8)
Mechanism of failure, n (%) 0.25
Stenosis 85 (42.1) 50 (40.3) 35 (44.9)
Regurgitation 68 (33.7) 47 (37.9) 21 (26.9)
Combined 49 (24.3) 27 (21.8) 22 (28.2)
STS indicates Society of Thoracic Surgeons; SAVR, surgical aortic valve replacement; and NYHA, New York Heart
Association.
*Comparisons between the CoreValve and Edwards SAPIEN groups.
†Calculated glomerular filtration rate 60 mL/min.
‡Presented as mean (interquartile range, 25th, 75th percentiles).
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Procedural Results
Table 2 depicts procedural results and 30-day outcome. There
were 14 procedural failures (6.9%) according to the registry
definition and 83 device failures according to the VARC
definition (41.1%). Most of the VARC device failures
(62.7%) were secondary to elevated postprocedural gradients
of moderate degree (mean gradients, 20–39 mm Hg). Proce-
dural success, according to the registry definition, and device
success according to the VARC definition were both higher
in the CoreValve group (96.8% versus 87.2%, P0.009 and
64.5% versus 50%, P0.04, respectively).
Thirty-one cases had initial device malposition (15.3%;
16.9% CoreValve versus 12.8% Edwards SAPIEN; P0.41)
(Figure 1A and 1B). Additional maneuvers during the proce-
dures included 11 attempts to retrieve the device during
CoreValve procedures (8.9%) and implantation of a second TAVR
device in 17 cases (8.1% CoreValve versus 9% Edwards
SAPIEN; P0.82). Postimplantation valvuloplasty was used in
25 cases (16.9% CoreValve versus 5.1% Edwards SAPIEN;
P0.01). Ostial left main coronary obstruction occurred in 7
cases (3.2% of CoreValve cases versus 3.8% of Edwards
SAPIEN cases; P1.0) (Figure 1C and 1D). In-hospital mortal-
ity in the patients with ostial coronary obstruction was 57.1%.
Three cases with ostial coronary obstruction appeared during
VIV procedures performed inside Mitroflow stented valves
(Sorin Group Inc, Vancouver, British Columbia, Canada), 2
Table 2. Procedural Characteristics and Early Results
Total
(n202)
CoreValve
(n124)
Edwards SAPIEN
(n78) P *
Procedural characteristics
Device size, mm, n (%) NA
23 62 (30.7) 0 62 (79.5)
26 115 (56.9) 99 (79.8) 16 (20.5)
29 25 (12.4) 25 (20.2) 0
Access, n (%) NA
Transfemoral 137 (67.8) 113 (91.1) 24 (30.8)
Transapical 54 (26.7) 0 54 (69.2)
Transaxillary 10 (5) 10 (8.1) 0
Transaortic 2 (1) 2 (1.6) 0
General anesthesia, n (%) 132 (65.3) 68 (54.8) 64 (82.1) 0.0001
Transesophageal echocardiography use, n (%) 105 (52) 49 (39.5) 56 (71.8) 0.0001
Procedural results, n (%)
Procedural success† 188 (93.1) 120 (96.8) 68 (87.2) 0.009
Preimplantation valvuloplasty 56 (27.7) 20 (16.1) 36 (46.2) 0.0001
Attempted device retrieval 11 (5.4) 11 (8.9) 0 NA
Need for a second TAVR valve 17 (8.4) 10 (8.1) 7 (9) 0.82
Postimplantation valvuloplasty 25 (12.4) 21 (16.9) 4 (5.1) 0.01
Ostial coronary obstruction 7 (3.5) 4 (3.2) 3 (3.8) 1.0
Need for an emergent surgery 4 (2) 1 (0.8) 3 (3.8) 0.3
Thirty-day outcome
Death, n (%) 17 (8.4) 9 (7.3) 8 (10.3) 0.45
Major stroke, n (%)‡ 4 (2) 2 (1.6) 2 (2.6) 0.64
Death or major stroke, n (%) 20 (10.4) 11 (8.9) 9 (11.5) 0.48
Major vascular complication, n (%)‡ 7 (3.5) 2 (1.6) 5 (6.4) 0.11
Need for a permanent pacemaker, n (%) 15 (7.4) 11 (8.9) 4 (5.1) 0.31
Aortic valve maximal gradients, mm Hg 28.414.1 25.312.9 33.514.5 0.0001
Aortic valve mean gradients, mm Hg 15.98.6 13.97.5 19.29.2 0.0001
Aortic regurgitation (2), n (%) 10 (5) 8 (6.5) 2 (2.6) 0.32
Left ventricular ejection fraction, % 51.311.8 50.612.4 52.410.6 0.31
NYHA functional class, n (%) 0.16
I 99 (49) 55 (44.4) 44 (56.4)
II 71 (35.1) 52 (41.9) 19 (24.4)
III 13 (6.4) 7 (5.6) 6 (7.7)
IV 2 (1) 1 (0.8) 1 (1.3)
TAVR indicates transcatheter aortic valve replacement; NYHA, New York Heart Association; and NA, not applicable.
*Comparisons between the CoreValve and Edwards SAPIEN groups.
†According to the registry definition.
‡According to the Valve Academic Research Consortium definition.
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cases in Freedom stentless valves (Sorin), 1 case in a stentless
CryoLife O’Brien valve (CryoLife International, Atlanta, GA),
and 1 in a stented Mosaic valve (Medtronic). The rate of ostial
coronary obstruction was 0.9% for stented bioprostheses (other
than Mitroflow) and 2.2% for stentless bioprostheses (other than
Freedom), without a statistically significant difference (P0.47).
There was an ostial coronary obstruction event in 7.7% of the
Mitroflow cases (more than in other stented valves; P0.049)
and in 50% of the Freedom stentless (more than in other stentless
valves; P0.02).
Thirty-Day Outcome
Median duration of hospital stay was 8 days (interquartile range,
6–12 days). At 30 days, 185 patients survived, 17 patients died
(8.4%), and no patient was lost to follow-up. There were no
differences between the CoreValve and Edwards SAPIEN
groups in mortality, major vascular complication, or stroke.
Overall, postprocedureal aortic valve gradients decreased to
28.414.1 mm Hg (maximum) and 15.98.6 mm Hg (mean).
Mean postprocedural gradients were 5 mm Hg higher in the
Edwards SAPIEN group than in the CoreValve group
(P0.0001). After the procedure, significant aortic regurgitation
(2) appeared in 10 cases (5%), and left ventricular ejection
fraction was 51.311.8%, which is similar to that measured
before the procedure at 50.512.2% (P0.62). There was no
difference between the CoreValve and Edwards SAPIEN groups
in the need for a permanent pacemaker implantation (8.9%
versus 5.1%, respectively; P0.31).
Postprocedural Gradients
Postprocedural gradients were assessed in 197 patients (5
patients died during the index procedure before the analysis).
High postprocedural gradients (mean gradients 20 mm Hg)
were recorded in 56 patients (28.4%): 26 in the CoreValve
group versus 30 in the Edwards SAPIEN group (Figure 2).
The rate of elevated postprocedural gradients was higher after
Edwards SAPIEN than after CoreValve implantations (40%
versus 21.3%, respectively; P0.0001). There was a signif-
icant difference in the rate of high postprocedural gradients
between the Edwards SAPIEN and the CoreValve groups for
VIV procedures performed inside small surgical bioprosthe-
ses (internal diameter 20 mm): 58.8% versus 20%, respec-
tively (P0.005); Figure 3 shows representative case exam-
ples. Table 3 shows the results of analysis for predictors for
high postprocedural gradients. The only independent predic-
tors were baseline surgical bioprosthetic valve area (odds
ratio, 0.87 per 0.1-cm2 increment; CI, 0.79–0.94; P0.001)
and implantation of the Edwards SAPIEN device versus
CoreValve (odds ratio, 2.28; CI, 1.17–4.43; P0.02). Preim-
plantation valvuloplasty and TAVR implantation inside a
stented bioprosthesis were not independent predictors for
elevated postprocedural gradients in multivariate analysis.
One-Year Clinical Results
The overall patients’ Kaplan–Meier survival curve is depicted
in Figure 4. Median follow-up time was 285 days (interquar-
tile range, 114–509 days). There were 23 deaths within the
first postprocedural year. At 1 year, the total number of
patients at risk was 87 (CoreValve, n48; Edwards SAPIEN,
n39), and the follow-up rate was 54.4%. The calculated
1-year survival was 85.8% (CI, 79.9–91.6%). There was no
significant difference in 1-year survival between patients
undergoing CoreValve VIV procedures (89%; CI, 82.1–
Figure 1. Case examples of device malposition
and ostial coronary obstruction during aortic
valve-in-valve implantations. A, CoreValve
embolization during implantation inside a Peri-
mount (Edwards Lifesciences, Irvine, CA) valve
(thick arrow) followed by delivery of a second
CoreValve in a correct position (thin arrow). B,
Edwards SAPIEN XT (arrow) dives into the left
ventricle during transapical implantation in a
Mosaic (Medtronic, Minneapolis, MN) valve (the
dotted line illustrates the target for implanta-
tion). That device was reimplanted after con-
version to open cardiac surgery. C, Transapical
Edwards SAPIEN implantations in a Mitroflow
(Sorin Group Inc, Vancouver, British Columbia,
Canada) 25-mm device showing the surgical
bioprosthetic valve leaflet (arrow) obstructing
the left coronary ostium. That patient had suc-
cessful coronary revascularization. D, Trans-
femoral CoreValve implantation in a Freedom
(Sorin) stentless surgical bioprosthesis. The
patient died suddenly on the second postoper-
ative day. Postmortem examination revealed
ostial left coronary artery obstructed by a bio-
prosthesis leaflet.
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95.8%) and those undergoing Edwards SAPIEN VIV proce-
dures (81.8%; CI, 71.9–91.6%; log rank P0.25).
Figure 5 shows hemodynamic and clinical results up to
1 year of follow-up. Thirty-day mean gradients, functional
class, and aortic regurgitation results were maintained at
1-year follow-up (P0.13, P0.33, P0.49, respectively).
Discussion
The present study is the first large, comprehensive evaluation
of a transcatheter approach for failed surgically inserted
aortic bioprostheses. According to the present analysis of
high-risk patients with degenerated bioprosthetic valves, in
most cases the VIV approach is clinically effective. The
improvement in patient functional capacity after device im-
plantation was clear: 84.1% of patients were classified as
having New York Heart Association class I/II early after the
procedure. Nevertheless, several safety and efficacy concerns
emerged, including a relatively high rate of device malposi-
tion, a cluster of ostial coronary obstruction events, and a
high rate of moderately elevated postprocedural gradients.
Procedural Efficacy
The VIV approach results in considerable hemodynamic
improvement, including a decrease in valve gradients and
aortic regurgitation level. Clinical results were maintained at
1-year follow-up among analyzed patients and are compara-
ble with other TAVR cohorts.8–10 Nevertheless, even though
implantation success according to the registry definition was
high (93.1%), the rate of VARC-defined “device success”
was relatively low (58.9%), which was primarily due to
elevated postprocedural gradients of moderate degree. It
should be emphasized that the VARC definition was created
and originally intended for TAVR procedures performed in
native aortic valves and not for VIV procedures.
High Postprocedural Gradients
Significantly elevated postprocedural gradients are common
after VIV. In the present registry, the rate of high postprocedural
gradients (mean,20 mm Hg) was relatively high (28.4%), and
the mean postprocedural gradient (15.9 mm Hg) was higher
than after procedures performed inside native aortic valves
(10 mm Hg).8–10 This is probably due to reduced area avail-
able for the functioning valve when implanted inside a surgical
bioprosthesis (ie, reduced potential orifice area) or patient-pros-
thetic mismatch. In an in vitro model of hemodynamic perfor-
mance of a 23-mm Edwards SAPIEN device within a degener-
ated surgical bioprosthesis, incomplete stent expansion resulted
in leaflet distortion when implanted in 19- and 21-mm Carpen-
tier Edwards bioprostheses.28
In the present analysis, the 2 independent predictors for
high postprocedural gradients (severity of bioprosthetic ste-
nosis and use of an Edwards SAPIEN device) are both
associated with reduced potential orifice area. The difference
between Edwards SAPIEN and CoreValve results is probably
secondary to the fundamental dissimilarity between the de-
vices: The functioning part of the Edwards SAPIEN valve is
located inside the native valve annulus (intra-annular), and
that of the CoreValve is usually located above that plane
(supra-annular). Consequently, the CoreValve device de-
pends much less on surgical bioprosthesis dimensions, and its
functioning part may have larger potential orifice area. In
support of this theory, in an in vitro evaluation, a custom-
designed supravalvular TAVR device has achieved more
favorable hemodynamic measurements.32 In the present reg-
istry, at 1-year follow-up there was no statistically significant
increase in valve gradients in comparison to early postproce-
dural gradients. However, the possible impact of elevated
gradients should be examined with longer follow-up.
Figure 2. Analysis of high postproce-
dural gradients (mean gradients
20 mm Hg) after valve-in-valve proce-
dures, according to surgical bioprosthe-
sis size: large (internal diameter
23 mm), intermediate (20 and 23),
and small (20). A, Mean gradients after
Edwards SAPIEN (red) procedures
according to the bioprosthesis size
(r0.353, P0.28). There was a negative
trend between the bioprosthesis size
and high postprocedural gradients rates:
23.1%, 37.8%, and 58.8%, respectively.
B, Mean gradients after CoreValve (blue)
procedures according to the bioprosthe-
sis size (r0.077, P0.40). Unlike after
the Edwards SAPIEN procedures, there
was almost no change in the rate of ele-
vated postprocedural gradients after
CoreValve procedures: large, 22.2%;
intermediate, 22.8%; small, 20%.
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Safety Hazards
Thirty-day mortality and stroke rates after VIV procedures
(8.4% and 2%, respectively) are comparable to those in other
TAVR cohorts.8–10 Nevertheless, there are 2 major safety
concerns when VIV is performed: device malposition and
ostial coronary obstruction. The relatively high malposition
rate during VIV cases (15.3%) could be secondary to the
relative lack of valvular calcification and, in some cases,
difficulty in defining the optimal target for implantation
during the procedure, particularly in stentless bioprostheses,
in which no anatomic markers are available.
Ostial left-main obstruction, which is reported only rarely
during native valve TAVR, seems to be more common during
VIV procedures (3.5%). This complication has a dreadful
prognosis. Most of the patients having ostial left-main ob-
struction died during their hospital stay. The propensity for
this complication is clearly related to the spatial geometry of
the surgical valve leaflets inside the aortic sinuses and seems
to be more common within the Mitroflow and Freedom
valves. The Mitroflow leaflets are unique, being relatively
long (13 mm) and mounted externally over the stent rather
than internally, as in most other stented bioprostheses.29
Implications for VIV Procedures
The VIV procedure is technically demanding and should be
reserved for highly experienced centers. Operators should be
skilled in the handling of device malposition, retrieval tech-
niques, and implantation of a second TAVR device, if
needed. During screening, the Heart Team must have all of
the information about and be familiar with the particular
characteristics of the surgical bioprosthesis: the mode of
degeneration and echocardiographic parameters (isolated para-
valvular regurgitation should be excluded); valve size (most
importantly, bioprosthesis internal diameter should be used for
TAVR device and size selection; because of better hemodynam-
ic results, CoreValve may be preferred in cases of small
bioprosthesis with internal diameter 20 mm); valve position
(intra-annular versus supra-annular); valve type (stented versus
stentless); the relation of the bioprosthetic valve to its radio-
opaque markers; and the risk for coronary obstruction when VIV
is performed inside that specific bioprosthesis.
Operators should be aware of the risk of device malposition,
and every effort should be taken to ensure correct localization
and overlap with the bioprosthesis sewing ring. One cannot
underestimate the importance of having coaxial positioning
during the final stage of device deployment. The use of trans-
Figure 3. Case examples of valve-in-valve procedures per-
formed inside small surgical bioprostheses. A, Transfemoral
implantation of 26-mm CoreValve inside a 19-mm Mitroflow
valve with an internal diameter of 15.4 mm. Postprocedural
maximum/mean gradients were reasonable: 29/14 mm Hg. B,
Transapical implantation of 23-mm Edwards SAPIEN inside a
21-mm Mitroflow valve with an internal diameter of 17 mm.
Postprocedural gradients were very high: 88/58 mm Hg.
Table 3. Predictors for Elevated Gradients After
Valve-in-Valve Procedures
Odds
Ratio
95% Confidence
Interval P
Univariate analysis
Patient age (y) 1.00 0.97–1.02 0.77
Female 0.95 0.65–1.48 0.76
LVEF (%) 1.02 1.00–1.04 0.04
NYHA functional class IV 0.47 0.24–0.92 0.03
Baseline aortic valve area* 1.17 1.07–1.27 0.0004
Baseline aortic regurgitation 2 2.71 1.43–5.14 0.002
Stented bioprosthesis 4.18 1.56–11.22 0.004
Small bioprostheses (ID 20 mm) 0.83 0.27–2.52 0.94
Preimplantation valvuloplasty 3.03 1.55–5.93 0.001
Use of Edwards SAPIEN device 2.46 1.31–4.64 0.005
Use of small TAVR device† 2.65 1.04–6.72 0.04
Postimplantation valvuloplasty 0.77 0.29–2.0 0.6
Multivariate analysis
Baseline aortic valve area* 0.87 0.79–0.94 0.001
Edwards SAPIEN 2.28 1.17–4.43 0.02
NYHA functional class IV 1.00 0.97–1.02 0.83
LVEF (%) 1.02 0.97–1.06 0.13
Baseline aortic regurgitation 2 1.04 0.49–2.17 0.93
Stented bioprosthesis 1.42 0.61–3.31 0.42
Small bioprostheses (ID 20 mm) 1.40 0.63–3.10 0.35
Preimplantation valvuloplasty 1.67 0.93–2.91 0.08
Use of small TAVR device† 2.85 0.41–17.32 0.84
Postimplantation valvuloplasty 1.57 0.62–3.81 0.38
LVEF indicates left ventricular ejection fraction; NYHA, New York Heart
Association; ID, internal diameter; and TAVR, transcatheter aortic valve
replacement.
*Per 0.1-cm2 increment.
†CoreValve 26 mm (vs 29 mm) and Edwards SAPIEN 23 mm (vs 26 mm).
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esophageal echocardiography during these procedures is encour-
aged, especially during procedures performed inside stentless
valves, where no radiopaque markers can assist in positioning.
The use of software that will possibly enable improved device
localization, such as the C-THV (Paieon Inc, Israel) or the Heart
Navigator (Philips, Eindhoven, Netherlands), may be helpful
and should be further evaluated.33
Although no case of acute hemodynamic instability after
preimplantation valvuloplasty was encountered in the registry,
the practice of balloon dilatation inside degenerative bioprosthe-
sis before valve implantation should be reserved for critically
stenotic bioprostheses and probably avoided in patients with
severe regurgitation. In comparison with native aortic valve
leaflets, surgical valves seem to be susceptible to tearing after
balloon valvuloplasty.34,35 That could lead to acute severe valve
regurgitation, debris embolization, and stroke. It must be em-
phasized, however, that avoiding preimplantation valvuloplasty
could result in a need for postimplantation balloon inflation, as
occurred in the registry CoreValve group.
When preimplantation valvuloplasty is utilized, the maneu-
ver may be used to examine the risk for ostial coronary
obstruction by injecting contrast above the inflated balloon
and evaluating the flow into the coronary arteries. Patients at
high risk of ostial coronary occlusion should probably be
managed conservatively, or, in selected Edwards SAPIEN
cases, a preventive wire may be inserted into the left main
coronary artery before device implantation.
Interestingly, the rate of pacemaker implantation after the
CoreValve VIV procedures (9%) was relatively low com-
pared with that after native aortic valve CoreValve proce-
dures. This is most likely due to some degree of protection
created by the surgical bioprosthesis frame, resulting in
diminished compression of the TAVR device on the interven-
tricular basal septum.36 Obviously, strict ECG monitoring
should be the standard of care after all TAVR procedures;
however, it seems that after CoreValve VIV implantations,
prolonged preventive use of a temporary pacemaker is not
warranted when no conduction abnormality appears.
Figure 4. Kaplan–Meier survival curve of
patients undergoing transcatheter aortic
valve replacement for degenerated bio-
prosthetic valve (valve-in-valve).
Figure 5. Clinical and hemodynamic
results of patients undergoing transcath-
eter aortic valve replacement for degen-
erated bioprosthetic valves (valve-in-
valve). Thirty-day mean valve gradients
(A), aortic regurgitation (B) and functional
class (C) results were maintained at
1-year follow-up (obtained in 81
patients). NYHA indicates New York
Heart Association.
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Implications for Cardiac Surgery
In the future, dependent on expanded clinical data, the VIV
approach may affect SAVR practice in several respects:
transcatheter treatment of patients with failed bioprosthetic
valves with markedly elevated risk for reoperation, selection
of valve class (biological much more than mechanical) and
valve type (with minimal risk for ostial coronary obstruction)
during surgery, and performance of surgical annular dilata-
tion in small aortic roots.
A randomized controlled trial comparing reoperative
SAVR and VIV in patients with failed bioprostheses has
never been executed, and because VIV treatment is still
infrequent, it will be quite difficult to conduct such a trial. As
a result, there are not enough data to justify VIV instead of
reoperation in most high-risk patients with failed aortic
bioprostheses. Nevertheless, VIV could be an acceptable
approach in carefully selected high-risk patients and in those
considered as having no option (ie, those with no other
effective treatment option for their illness).
VIV practice may also affect the selection of valve type
during SAVR. A less invasive approach for failed biopros-
theses could definitely be an argument in favor of using
bioprosthesis in younger patients undergoing SAVR. In
addition, surgical valves with increased risk for ostial coro-
nary obstruction after VIV should probably be used less
frequently during SAVR because the risk of later biopros-
thetic failure and the possible need for a subsequent VIV
procedure should be taken into account.
Limitations
Because the VIV approach is novel, 1-year follow-up was
reached in only 87 patients, less than half of the original
group evaluated. Therefore, long-term results of the registry
data should be analyzed with caution. Registry results reveal
that elevated gradients are relatively common after VIV
procedures. However, the study was not powered to correlate
these echocardiographic results and clinical outcomes. For
that evaluation, another trial including a larger patient group
followed for a longer time period might be beneficial.
Conclusion
The VIV procedure is clinically effective in the vast majority
of patients with degenerated stenotic or regurgitant biopros-
thetic valves. Short- and intermediate-term results after these
procedures are favorable. Safety and efficacy concerns in-
clude device malposition, ostial coronary obstruction, and
high postprocedural gradients.
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CLINICAL PERSPECTIVE
In the last decade, bioprosthetic valves have been used more commonly during surgical valve replacements; it is estimated
that in subsequent years, many patients will suffer from failed surgical bioprostheses. The Global Valve-in-Valve Registry,
which includes in the present analysis 202 patients from 38 centers, is the first large, comprehensive evaluation of
transcatheter aortic valve replacement with the use of either Edwards SAPIEN (Edwards Lifesciences, Irvine, CA) or
CoreValve (Medtronic, Minneapolis, MN) devices for failed surgically inserted aortic bioprostheses, including 1-year
clinical and echocardiographic analyses. According to the registry, the valve-in-valve approach is effective and relatively
safe. Improvement in patient functional capacity was clear: 84.1% of treated patients were classified as New York Heart
Association class I/II early after the procedure. Clinical and hemodynamic results are maintained in 1-year follow-up.
Thirty-day mortality and stroke rates (8.4% and 2%, respectively) are comparable to those in other transcatheter aortic
valve replacement cohorts. An efficacy concern involved moderately elevated postprocedural gradients, with predictors in
multivariate analysis that include the degree of bioprosthesis stenosis and treatment with an Edwards SAPIEN inside a
small bioprosthesis. Safety concerns included ostial coronary obstruction (3.5%) and device malposition (15.3%) resulting
in relatively high rates of a need for implantation of another transcatheter aortic valve replacement device (8.4%) and
retrieval of a CoreValve (8.9%). Operators of valve-in-valve procedures should be skilled in handling device malposition
and related technical maneuvers, if needed. The possible impact on cardiac surgery practice includes referral of patients
with failed bioprostheses who are at very high surgical risk to valve-in-valve and selection of valve class during surgery
(mechanical versus biological), in favor of the use of bioprostheses.
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SUPPLEMENTAL MATERIAL 
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Piazza, MD, PhD, Domenico Mazzitelli, MD 
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15 John Webb, MD, Stefan Toggweiler, MD, Anson 
Cheung, MD, Jian Ye, MD 
St Paul’s, Vancouver, Canada 
13 David Hildick-Smith, MD, Uday H Trivedi, FRCS Sussex Cardiac Centre, Brighton, UK 
12 Alec Vahanian, MD, Dominique Himbert, MD, Fleur 
Descoutures, MD 
Hospital Bichat, Paris, France 
11 Antonio Colombo, MD, Azeem Latib, MD, Matteo 
Montorfano MD, Alaide Chieffo MD, Francesco 
Maisano MD  
San Raffaele Scientific Institute, Milan, Italy 
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Appendix 2. Degenerated bioprostheses included in the Global Valve-in-Valve Registry 
Stented (n= 155) Stentless (n= 47) 
 n %  n % 
Carpentier Edwards (Edwards 
Lifesciences, Irvine, CA) 
61 39.4 Homograft 14 29.8 
Mitroflow (Sorin Group Inc, Vancouver, 
Canada) 
39 25.2 Biocor (St. Jude) 10 21.3 
Mosaic (Medtronic, Minneapolis, MN) 15 9.7 
Cryolife O’Brien (Cryolife 
International, Atlanta, GA) 
6 12.8 
Epic (St. Jude Medical, St. Paul, MN) 13 8.4 Freestyle (Medtronic) 4 8.5 
Hancock (Medtronic) 13 8.4 Freedom (Sorin) 4 8.5 
Others 14 9.0 Toronto SPV (St. Jude) 4 8.5 
   Prima (Edwards) 2 4.3 
   Others 3 6.4 
   
   
Label-size n %    
19-mm 6 3 
   
21-mm 47 23.3 
   
23-mm 74 36.6 
   
25-mm 47 23.3 
   
27-mm 9 4.5 
   
Others 19 9.4    
 
 
